Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)
China · Delayed Price · Currency is CNY 10.03
-0.15 (-1.47%)
Jul 30, 2026, 10:55 AM CST
SHA:603439 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,676 | 1,703 | 2,144 | 1,635 | 1,201 | 938.97 |
Revenue Growth | -21.35% | -20.59% | 31.16% | 36.10% | 27.94% | 48.99% |
Gross Profit Gross Profit Growth | 1,189 | 1,184 | 1,491 | 1,197 | 861.8 | 661.89 |
Operating Income Operating Income Growth | 190.7 | 186.06 | 328.34 | 267.22 | 204.62 | 151.92 |
Net Income Net Income Growth | 48.72 | 46.25 | 274.03 | 292.7 | 201.28 | 152.28 |
Earnings Per Share EPS Growth | 0.12 | 0.11 | 0.67 | 0.71 | 0.49 | 0.37 |
EPS Growth | -81.38% | -83.58% | -5.63% | 44.90% | 32.43% | 54.17% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 376.3 | 409.61 | 499.02 | 622.87 | 630.79 | 642.22 |
Total Debt Total Debt Growth | 707.84 | 758.32 | 606.68 | 555.02 | 205.67 | 200 |
Net Cash (Debt) Net Cash Growth | -331.54 | -348.71 | -107.67 | 67.86 | 425.12 | 442.22 |
Net Cash Growth | - | - | - | -84.04% | -3.87% | 16.36% |
Net Cash Per Share Net Cash Per Share Growth | -0.80 | -0.83 | -0.26 | 0.16 | 1.03 | 1.07 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 193.25 | 164.58 | 107.07 | 276.7 | 293.29 | 155.04 |
Capital Expenditures CapEx Growth | -25.89 | -25.84 | -45.2 | -108.73 | -119.91 | -26.08 |
Free Cash Flow Free Cash Flow Growth | 167.36 | 138.74 | 61.87 | 167.97 | 173.38 | 128.96 |
Free Cash Flow Growth | 269.53% | 124.23% | -63.16% | -3.12% | 34.45% | 1017.56% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 70.96% | 69.50% | 69.55% | 73.21% | 71.74% | 70.49% |
Operating Margin | 11.38% | 10.93% | 15.31% | 16.34% | 17.03% | 16.18% |
Pretax Margin | 4.25% | 3.98% | 15.16% | 20.43% | 18.53% | 18.81% |
Profit Margin | 2.91% | 2.72% | 12.78% | 17.90% | 16.75% | 16.22% |
FCF Margin | 9.99% | 8.15% | 2.89% | 10.27% | 14.43% | 13.73% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.060 | 0.060 | 0.340 | 0.200 | 0.100 |
Dividend Per Share Growth | -82.35% | -82.35% | 70.00% | 100.00% | - |
Dividend Yield | 0.59% | 0.52% | 2.70% | 1.11% | 0.77% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 87.04 | 102.38 | 18.99 | 26.44 | 28.01 | 42.58 |
Forward PE | - | 10.60 | 13.81 | 26.53 | 25.89 | - |
P/FCF Ratio | 24.62 | 34.13 | 84.12 | 46.07 | 32.51 | 50.27 |
PS Ratio | 2.46 | 2.78 | 2.43 | 4.73 | 4.69 | 6.91 |